Myoinositol: The Bridge (PONTI) to Reach a Healthy Pregnancy

Overview

Journal Int J Endocrinol

Publisher Wiley

Specialty Endocrinology

Date 2017 Mar 1

PMID 28243254

Citations 9

Authors

Pietro Cavalli

Elena Ronda

Affiliations

Soon will be listed here.

Abstract

The use of folic acid in the periconceptional period can prevent about 70% of neural tube defects (NTDs). In the remaining cases, no medical prevention is available, and those conditions should be defined as folate-resistant NTDs. Rodent models suggest that some folate-resistant NTDs can be prevented by inositol (myoinositol and chiroinositol) supplementation prior to pregnancy. Should folic acid be combined with myoinositol periconceptional supplementation to reduce the overall risk of NTDs even in humans? Hereafter, we discuss the results from the PONTI study that strongly support both the effectiveness and safety of myoinositol periconceptional supplementation in preventing human NTDs. We further report on the largest case series of pregnancies treated with myoinositol and folic acid. At our institution, a sequential study during 12 years involved mothers at risk of fetal NTDs, and 29 babies from 27 pregnancies were born after periconceptional combined myoinositol and folic acid supplementation. No case of NTDs was observed, despite the high recurrence risk in the mothers. Taken together, those data suggest that periconceptional folic acid plus myoinositol can reduce both the occurrence and recurrence risks of NTDs in a greater number of cases than folic acid alone.

Citing Articles

Inositols and female reproduction disorders: a consensus statement from the working group of the Club of the Italian Society of Endocrinology (SIE)-Women's Endocrinology.

Moretti C, Bonomi M, Dionese P, Federici S, Fulghesu A, Giannelli J J Endocrinol Invest. 2024; 47(9):2111-2141.

PMID: 39009925 DOI: 10.1007/s40618-024-02363-w.

A Markov-model simulation of IVF programs for PCOS patients indicates that coupling myo-Inositol with rFSH is cost-effective for the Italian Health System.

Beresniak A, Russo M, Forte G, Lagana A, Oliva M, Aragona C Sci Rep. 2023; 13(1):17789.

PMID: 37853019 PMC: 10584971. DOI: 10.1038/s41598-023-44055-0.

A comprehensive review on infant formula: nutritional and functional constituents, recent trends in processing and its impact on infants' gut microbiota.

Bakshi S, Paswan V, Yadav S, Bhinchhar B, Kharkwal S, Rose H Front Nutr. 2023; 10:1194679.

PMID: 37415910 PMC: 10320619. DOI: 10.3389/fnut.2023.1194679.

BMP/Smad Pathway Is Involved in Lithium Carbonate-Induced Neural-Tube Defects in Mice and Neural Stem Cells.

Yang A, Li S, Zhang Y, Wang X, Guan Z, Zhu Z Int J Mol Sci. 2022; 23(23).

PMID: 36499158 PMC: 9735442. DOI: 10.3390/ijms232314831.

Melatonin and Myo-Inositol: Supporting Reproduction from the Oocyte to Birth.

Russo M, Forte G, Oliva M, Lagana A, Unfer V Int J Mol Sci. 2021; 22(16).

PMID: 34445135 PMC: 8395120. DOI: 10.3390/ijms22168433.

References

Baker L, Piddington R, Goldman A, Egler J, Moehring J . Myo-inositol and prostaglandins reverse the glucose inhibition of neural tube fusion in cultured mouse embryos. Diabetologia. 1990; 33(10):593-6. DOI: 10.1007/BF00400202. View

Wilson M, Hugge C, Bielinska M, Nicholas P, Majerus P, Wilson D . Neural tube defects in mice with reduced levels of inositol 1,3,4-trisphosphate 5/6-kinase. Proc Natl Acad Sci U S A. 2009; 106(24):9831-5. PMC: 2701051. DOI: 10.1073/pnas.0904172106. View

Glasziou P, Chalmers I, Rawlins M, McCulloch P . When are randomised trials unnecessary? Picking signal from noise. BMJ. 2007; 334(7589):349-51. PMC: 1800999. DOI: 10.1136/bmj.39070.527986.68. View

Cogram P, Hynes A, Dunlevy L, Greene N, Copp A . Specific isoforms of protein kinase C are essential for prevention of folate-resistant neural tube defects by inositol. Hum Mol Genet. 2003; 13(1):7-14. DOI: 10.1093/hmg/ddh003. View

Cavalli P, Tonni G, Grosso E, Poggiani C . Effects of inositol supplementation in a cohort of mothers at risk of producing an NTD pregnancy. Birth Defects Res A Clin Mol Teratol. 2011; 91(11):962-5. DOI: 10.1002/bdra.22853. View

Copp A . Relationship between timing of posterior neuropore closure and development of spinal neural tube defects in mutant (curly tail) and normal mouse embryos in culture. J Embryol Exp Morphol. 1985; 88:39-54. View

Cockroft D . Changes with gestational age in the nutritional requirements of postimplantation rat embryos in culture. Teratology. 1988; 38(3):281-90. DOI: 10.1002/tera.1420380312. View

Fleming A, Copp A . Embryonic folate metabolism and mouse neural tube defects. Science. 1998; 280(5372):2107-9. DOI: 10.1126/science.280.5372.2107. View

Cavalli P, Copp A . Inositol and folate resistant neural tube defects. J Med Genet. 2002; 39(2):E5. PMC: 1735032. DOI: 10.1136/jmg.39.2.e5. View

10.

Cockroft D, Brook F, Copp A . Inositol deficiency increases the susceptibility to neural tube defects of genetically predisposed (curly tail) mouse embryos in vitro. Teratology. 1992; 45(2):223-32. DOI: 10.1002/tera.1420450216. View

11.

Greene N, Copp A . Inositol prevents folate-resistant neural tube defects in the mouse. Nat Med. 1997; 3(1):60-6. DOI: 10.1038/nm0197-60. View

12.

De-Regil L, Fernandez-Gaxiola A, Dowswell T, Pena-Rosas J . Effects and safety of periconceptional folate supplementation for preventing birth defects. Cochrane Database Syst Rev. 2010; (10):CD007950. PMC: 4160020. DOI: 10.1002/14651858.CD007950.pub2. View

13.

Blencowe H, Cousens S, Modell B, Lawn J . Folic acid to reduce neonatal mortality from neural tube disorders. Int J Epidemiol. 2010; 39 Suppl 1:i110-21. PMC: 2845867. DOI: 10.1093/ije/dyq028. View

14.

Dolk H, Loane M, Garne E . The prevalence of congenital anomalies in Europe. Adv Exp Med Biol. 2010; 686:349-64. DOI: 10.1007/978-90-481-9485-8_20. View

15.

Majerus P, Wilson D, Zhang C, Nicholas P, Wilson M . Expression of inositol 1,3,4-trisphosphate 5/6-kinase (ITPK1) and its role in neural tube defects. Adv Enzyme Regul. 2009; 50(1):365-72. PMC: 2862868. DOI: 10.1016/j.advenzreg.2009.10.017. View

16.

Groenen P, Peer P, Wevers R, Swinkels D, Franke B, Mariman E . Maternal myo-inositol, glucose, and zinc status is associated with the risk of offspring with spina bifida. Am J Obstet Gynecol. 2004; 189(6):1713-9. DOI: 10.1016/s0002-9378(03)00807-x. View

17.

Hashimoto M, Akazawa S, Akazawa M, Akashi M, Yamamoto H, Maeda Y . Effects of hyperglycaemia on sorbitol and myo-inositol contents of cultured embryos: treatment with aldose reductase inhibitor and myo-inositol supplementation. Diabetologia. 1990; 33(10):597-602. DOI: 10.1007/BF00400203. View

18.

Stiefel D, Copp A, Meuli M . Fetal spina bifida in a mouse model: loss of neural function in utero. J Neurosurg. 2007; 106(3 Suppl):213-21. PMC: 3651953. DOI: 10.3171/ped.2007.106.3.213. View

19.

Boyd P, Devigan C, Khoshnood B, Loane M, Garne E, Dolk H . Survey of prenatal screening policies in Europe for structural malformations and chromosome anomalies, and their impact on detection and termination rates for neural tube defects and Down's syndrome. BJOG. 2008; 115(6):689-96. PMC: 2344123. DOI: 10.1111/j.1471-0528.2008.01700.x. View

20.

Seller M . Vitamins, folic acid and the cause and prevention of neural tube defects. Ciba Found Symp. 1994; 181:161-73; discussion 173-9. DOI: 10.1002/9780470514559.ch10. View